NCT07317726

Brief Summary

Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease. As carcinoid tumors are rare and there are no data supporting stage migration, the aim of this study was to perform comprehensive trends analysis in addition to survival analysis over two decades.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
93,481

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2000

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2000

Completed
22.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2022

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

December 19, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

January 5, 2026

Completed
Last Updated

January 5, 2026

Status Verified

December 1, 2025

Enrollment Period

22.1 years

First QC Date

December 19, 2025

Last Update Submit

December 19, 2025

Conditions

Carcinoid TumorSEER Database AnalysisStage

Outcome Measures

Primary Outcomes (2)

  • The percent change and annual percent change for gastrointestinal carcinoids

    2000-2022

  • the percent change and annual percent change for gastrointestinal carcinoids across different stage distribution at diagnosis (localized, regional, distant, unknown)

    2000-2022

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

the investigators analyzed the data from cancer registries participating in Surveillance, Epidemiology, and End Results (SEER) software for patients diagnosed with primary GI carcinoid tumors from 2000-2022 using a rate session to calculate the percent change and annual percent change in addition to incidence rates.

You may qualify if:

  • patients with gastrointestinal carcinoid tumors

You may not qualify if:

  • patients with unknown age data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Carcinoid Tumor

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsAdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident physician of gastroenterology

Study Record Dates

First Submitted

December 19, 2025

First Posted

January 5, 2026

Study Start

December 1, 2000

Primary Completion

December 30, 2022

Study Completion

December 30, 2022

Last Updated

January 5, 2026

Record last verified: 2025-12